Sigma Healthcare Limited (ASX:SIG)
announced the FY20 EBITDA guidance after the announcement on new first-line agreement with My Chemist/Chemist Warehouse Group (MC/CW Group).
The new agreement will lift the annualised sales by $700 - $800 million when at a full run rate, which is expected to be from 1 July 2020.
The company predicted the FY20 EBITDA of approximately $46-47 million which includes $57-58 million benefits from the adoption of new accounting standards (AASB 16 Leases).
The company’s FY21 growth is expected to accelerate from both the core business and MC/CW Group.
On 13 December 2019, the stock traded higher by 3.9%, at $0.660, relative to the previous close.